Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone capsule plus capecitabine in metastatic HER2-negative breast cancer
ChiCTR2400085074Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and capecitabine in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoints: Objective response rate and Overall survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
utidelonecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400085074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085074.